Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $37,740.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the transaction, the vice president directly owned 74,424 shares of the company’s stock, valued at $5,617,523.52. The trade was a 0.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

Get ANI Pharmaceuticals alerts:

• On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $81.84, for a total transaction of $40,920.00.
• On Friday, June 12th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.03, for a total transaction of $41,015.00.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $76.54 on Friday. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 52 week low of $70.15 and a 52 week high of $99.50. The stock’s 50-day moving average price is $80.82 and its 200-day moving average price is $79.03. The stock has a market capitalization of $1.76 billion, a PE ratio of 16.50 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. During the same quarter in the prior year, the firm posted $1.80 EPS. ANI Pharmaceuticals’s quarterly revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

Institutional Trading of ANI Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals in the first quarter worth approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after acquiring an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in ANI Pharmaceuticals by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after purchasing an additional 423 shares during the period. Jane Street Group LLC purchased a new stake in ANI Pharmaceuticals in the first quarter valued at $2,706,000. Finally, Norges Bank acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $625,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on ANIP shares. Canaccord Genuity Group cut their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Finally, Guggenheim reduced their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $105.83.

Read Our Latest Research Report on ANIP

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Featured Articles

• Five stocks we like better than ANI Pharmaceuticals
• Is Best Buy the AI Winner Hiding in the Electronics Aisle?
• Applied Materials Beat Everything but Wall Street’s Expectations for Margins
• Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
• Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.